Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
The analysis of operating activity ratios from 2017 to 2021 reveals a period of efficiency gains followed by a notable deterioration in working capital management, particularly regarding inventory turnover and the overall cash cycle.
- Inventory Management Efficiency
- Inventory turnover experienced a positive trend peaking at 2.43 in 2019, which corresponded with the shortest average inventory processing period of 150 days. However, a subsequent decline is evident, with turnover falling to 1.56 and the processing period extending to 234 days by 2021. This indicates a slowing of product movement and a significant increase in the time required to convert inventory into sales.
- Receivables and Collection Performance
- Receivables management remained remarkably stable throughout the observed period. The receivables turnover fluctuated minimally between 5.56 and 6.05, and the average collection period remained consistent, ranging between 60 and 66 days. This suggests a disciplined and predictable credit collection process with little to no volatility in customer payment behavior.
- Payables and Liability Management
- A general downward trend is observed in payables turnover, moving from 4.12 in 2017 to 3.58 in 2021. This is mirrored by an increase in the average payables payment period, which rose to a peak of 102 days in 2021. The extension of payment terms suggests a strategic shift toward utilizing supplier credit to preserve cash liquidity.
- Operating Cycle and Cash Conversion
- The operating cycle and cash conversion cycle both reached their lowest points in 2019, at 210 days and 111 days respectively. Since then, a sharp upward trend has emerged, with the cash conversion cycle extending to 196 days by 2021. This expansion is primarily driven by the increase in the inventory processing period, which has largely offset the liquidity benefits gained from the extended payables payment period.
- Working Capital Utilization
- Working capital turnover showed an initial increase, peaking at 3.40 in 2020, before dropping to 2.49 in 2021. This decline in the final year indicates a reduced efficiency in using working capital to generate revenue, aligning with the broader trends of slowing inventory movement and an expanding cash conversion cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,109,700) | 1,805,200) | 1,955,400) | 1,816,300) | 1,630,000) | |
| Inventory | 1,351,500) | 1,068,600) | 804,200) | 929,900) | 902,700) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 1.56 | 1.69 | 2.43 | 1.95 | 1.81 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.58 | — | — | — | — | |
| Amgen Inc. | 1.58 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 4.74 | — | — | — | — | |
| Danaher Corp. | 4.16 | — | — | — | — | |
| Eli Lilly & Co. | 1.88 | — | — | — | — | |
| Gilead Sciences Inc. | 4.08 | — | — | — | — | |
| Johnson & Johnson | 2.87 | — | — | — | — | |
| Merck & Co. Inc. | 2.29 | — | — | — | — | |
| Pfizer Inc. | 3.40 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 1.25 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 3.88 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 2.56 | — | — | — | — | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.11 | — | — | — | — | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.90 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Inventory turnover = Cost of sales, excluding amortization and impairment of acquired intangible assets ÷ Inventory
= 2,109,700 ÷ 1,351,500 = 1.56
2 Click competitor name to see calculations.
The analysis of inventory management from 2017 to 2021 reveals a fluctuating trend in operational efficiency, characterized by a peak in turnover in 2019 followed by a steady decline in the subsequent two years.
- Cost of Sales Trends
- The cost of sales, excluding amortization and impairment of acquired intangible assets, exhibited an overall upward trajectory, rising from US$ 1,630,000 thousand in 2017 to US$ 2,109,700 thousand in 2021. A temporary contraction occurred in 2020, where costs decreased to US$ 1,805,200 thousand before rebounding sharply in 2021.
- Inventory Level Variations
- Inventory levels remained relatively stable between 2017 and 2019, reaching a period low of US$ 804,200 thousand in 2019. However, a significant expansion in inventory holdings was observed thereafter, with balances increasing to US$ 1,068,600 thousand in 2020 and reaching a peak of US$ 1,351,500 thousand by December 31, 2021.
- Inventory Turnover Efficiency
- The inventory turnover ratio showed a period of improvement between 2017 and 2019, peaking at 2.43. This indicates an increase in the efficiency of moving stock relative to the cost of sales. Conversely, from 2020 onward, the ratio declined to 1.69 and further to 1.56 in 2021. This downward trend suggests that inventory accumulation has outpaced the growth in the cost of sales, resulting in slower inventory movement and a decrease in short-term operating efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Receivables Turnover
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Product, net | 8,846,900) | 10,692,200) | 11,379,800) | 10,886,800) | 10,354,700) | |
| Accounts receivable, net | 1,549,400) | 1,913,800) | 1,880,500) | 1,958,500) | 1,787,000) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 5.71 | 5.59 | 6.05 | 5.56 | 5.79 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.63 | — | — | — | — | |
| Amgen Inc. | 4.96 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 5.65 | — | — | — | — | |
| Danaher Corp. | 6.36 | — | — | — | — | |
| Eli Lilly & Co. | 4.24 | — | — | — | — | |
| Gilead Sciences Inc. | 6.01 | — | — | — | — | |
| Johnson & Johnson | 6.14 | — | — | — | — | |
| Merck & Co. Inc. | 5.28 | — | — | — | — | |
| Pfizer Inc. | 7.16 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.66 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 4.92 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 6.66 | — | — | — | — | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.54 | — | — | — | — | |
| Receivables Turnover, Industry | ||||||
| Health Care | 8.00 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Receivables turnover = Product, net ÷ Accounts receivable, net
= 8,846,900 ÷ 1,549,400 = 5.71
2 Click competitor name to see calculations.
An analysis of the short-term operating activity reveals a period of moderate revenue growth followed by a notable decline, while the efficiency of receivables collection remained remarkably consistent over the five-year period.
- Revenue and Asset Trends
- Net product revenue experienced growth from 2017 through 2019, peaking at 11,379,800 thousand US dollars. However, a downward trajectory began in 2020, culminating in a significant decrease to 8,846,900 thousand US dollars by December 31, 2021. Accounts receivable, net, followed a non-linear path, increasing initially to a peak of 1,958,500 thousand US dollars in 2018 before declining to 1,549,400 thousand US dollars in 2021, coinciding with the contraction in product revenue.
- Receivables Turnover Performance
- The receivables turnover ratio exhibited high stability, fluctuating within a narrow range between a low of 5.56 in 2018 and a high of 6.05 in 2019. Despite the substantial drop in net product revenue observed in 2021, the turnover ratio remained resilient at 5.71, suggesting that the company maintained its collection efficiency regardless of the overall volume of sales.
- Operating Efficiency Insights
- The consistency of the turnover ratio indicates a disciplined credit policy and a stable collection cycle. The alignment between the decrease in accounts receivable and the decrease in net product revenue in 2021 prevents the turnover ratio from deteriorating, demonstrating that the company successfully scaled its receivables in proportion to its shrinking revenue base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Payables Turnover
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,109,700) | 1,805,200) | 1,955,400) | 1,816,300) | 1,630,000) | |
| Accounts payable | 589,200) | 454,900) | 530,800) | 370,500) | 395,500) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 3.58 | 3.97 | 3.68 | 4.90 | 4.12 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 6.05 | — | — | — | — | |
| Amgen Inc. | 4.72 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 3.37 | — | — | — | — | |
| Danaher Corp. | 4.48 | — | — | — | — | |
| Eli Lilly & Co. | 4.38 | — | — | — | — | |
| Gilead Sciences Inc. | 9.36 | — | — | — | — | |
| Johnson & Johnson | 2.70 | — | — | — | — | |
| Merck & Co. Inc. | 2.96 | — | — | — | — | |
| Pfizer Inc. | 5.53 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 4.32 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 6.83 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 4.64 | — | — | — | — | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.23 | — | — | — | — | |
| Payables Turnover, Industry | ||||||
| Health Care | 5.84 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Payables turnover = Cost of sales, excluding amortization and impairment of acquired intangible assets ÷ Accounts payable
= 2,109,700 ÷ 589,200 = 3.58
2 Click competitor name to see calculations.
The payables turnover ratio exhibits notable volatility over the five-year period from 2017 to 2021, reflecting shifts in the management of short-term obligations relative to the cost of sales. While the ratio peaked in 2018, a general downward trajectory is observable toward the end of the period, suggesting an extension in the average time taken to settle obligations with suppliers.
- Cost of Sales and Liability Trends
- Cost of sales, excluding amortization and impairment, grew from 1.63 billion USD in 2017 to a peak of 2.11 billion USD in 2021, with a temporary contraction in 2020. Concurrently, accounts payable demonstrated significant fluctuations, increasing from 395.5 million USD in 2017 to 589.2 million USD in 2021. The most substantial increase in payables occurred between 2018 and 2019, where obligations rose from 370.5 million USD to 530.8 million USD.
- Payables Turnover Analysis
- The turnover ratio rose from 4.12 in 2017 to a period high of 4.90 in 2018, indicating a more rapid settlement of supplier invoices. However, this trend reversed in 2019, with the ratio dropping to 3.68. Following a brief recovery to 3.97 in 2020, the ratio reached its lowest point of 3.58 in 2021. This decline indicates that accounts payable grew at a faster rate than the associated cost of sales during the latter part of the analysis period.
- Operational Implications
- The reduction in the payables turnover ratio toward 2021 suggests a strategic extension of the payment cycle. By increasing the balance of accounts payable relative to the cost of sales, the entity has effectively increased its reliance on supplier financing, which may serve to preserve cash flow for other operational requirements.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Working Capital Turnover
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current assets | 7,856,500) | 6,887,100) | 8,381,800) | 7,640,900) | 7,873,300) | |
| Less: Current liabilities | 4,298,200) | 3,742,200) | 4,863,800) | 3,295,200) | 3,368,200) | |
| Working capital | 3,558,300) | 3,144,900) | 3,518,000) | 4,345,700) | 4,505,100) | |
| Product, net | 8,846,900) | 10,692,200) | 11,379,800) | 10,886,800) | 10,354,700) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 2.49 | 3.40 | 3.23 | 2.51 | 2.30 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 3.37 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 3.95 | — | — | — | — | |
| Danaher Corp. | 8.40 | — | — | — | — | |
| Eli Lilly & Co. | 8.33 | — | — | — | — | |
| Gilead Sciences Inc. | 8.54 | — | — | — | — | |
| Johnson & Johnson | 5.95 | — | — | — | — | |
| Merck & Co. Inc. | 7.62 | — | — | — | — | |
| Pfizer Inc. | 4.83 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 1.59 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 5.87 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 1.02 | — | — | — | — | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.87 | — | — | — | — | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 8.57 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Working capital turnover = Product, net ÷ Working capital
= 8,846,900 ÷ 3,558,300 = 2.49
2 Click competitor name to see calculations.
Analysis of working capital efficiency reveals a period of increasing operational productivity followed by a notable decline in the final year of the observation period. The working capital turnover ratio exhibited a consistent upward trend from 2017 through 2020 before reversing in 2021.
- Working Capital Trends
- A gradual reduction in working capital was observed between 2017 and 2020, with values decreasing from 4,505,100 thousand USD to 3,144,900 thousand USD. This contraction was followed by a moderate increase to 3,558,300 thousand USD by December 31, 2021.
- Net Product Revenue Performance
- Net product revenue experienced growth from 2017 to a peak of 11,379,800 thousand USD in 2019. Subsequently, a downward trajectory began, resulting in a decrease to 10,692,200 thousand USD in 2020 and a further decline to 8,846,900 thousand USD by the end of 2021.
- Working Capital Turnover Efficiency
- The efficiency of working capital utilization improved steadily from 2017 to 2020, as the turnover ratio rose from 2.30 to 3.40. This indicates a higher volume of net sales generated per unit of working capital during this period. However, this trend reversed sharply in 2021, with the ratio falling to 2.49, driven by the simultaneous decrease in net product revenue and a simultaneous increase in the working capital base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Inventory Processing Period
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 1.56 | 1.69 | 2.43 | 1.95 | 1.81 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 234 | 216 | 150 | 187 | 202 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 65 | — | — | — | — | |
| Amgen Inc. | 231 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 77 | — | — | — | — | |
| Danaher Corp. | 88 | — | — | — | — | |
| Eli Lilly & Co. | 194 | — | — | — | — | |
| Gilead Sciences Inc. | 89 | — | — | — | — | |
| Johnson & Johnson | 127 | — | — | — | — | |
| Merck & Co. Inc. | 159 | — | — | — | — | |
| Pfizer Inc. | 107 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 292 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 94 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 143 | — | — | — | — | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 117 | — | — | — | — | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 46 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.56 = 234
2 Click competitor name to see calculations.
The evaluation of operating activity ratios reveals a non-linear trend in inventory management efficiency from 2017 to 2021. Operational effectiveness peaked in 2019 before experiencing a marked decline in the following two fiscal years.
- Inventory Turnover Analysis
- The inventory turnover ratio improved from 1.81 in 2017 to a peak of 2.43 in 2019, indicating an acceleration in the rate at which inventory was utilized and sold. This efficiency gain was not sustained, as the ratio declined to 1.69 in 2020 and reached a five-year low of 1.56 in 2021, suggesting a slowdown in inventory movement.
- Average Inventory Processing Period Analysis
- The duration required to process inventory decreased from 202 days in 2017 to 150 days in 2019, signaling optimal short-term asset utilization. Following this low point, the processing period lengthened significantly, rising to 216 days in 2020 and further increasing to 234 days by the end of 2021. This upward trend indicates that inventory remained on hand longer, reflecting a decrease in operational velocity compared to the 2019 peak.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Receivable Collection Period
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 5.71 | 5.59 | 6.05 | 5.56 | 5.79 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 64 | 65 | 60 | 66 | 63 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 65 | — | — | — | — | |
| Amgen Inc. | 74 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 65 | — | — | — | — | |
| Danaher Corp. | 57 | — | — | — | — | |
| Eli Lilly & Co. | 86 | — | — | — | — | |
| Gilead Sciences Inc. | 61 | — | — | — | — | |
| Johnson & Johnson | 59 | — | — | — | — | |
| Merck & Co. Inc. | 69 | — | — | — | — | |
| Pfizer Inc. | 51 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 137 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 74 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 55 | — | — | — | — | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 66 | — | — | — | — | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 46 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.71 = 64
2 Click competitor name to see calculations.
The analysis of operating activity ratios from 2017 to 2021 reveals a high degree of stability in the management of accounts receivable. The company maintains a consistent efficiency in converting its receivables into cash, with both turnover and collection metrics exhibiting minimal volatility over the five-year period.
- Receivables Turnover
- The receivables turnover ratio fluctuated within a narrow band, ranging from a low of 5.56 in 2018 to a peak of 6.05 in 2019. After the 2019 peak, the ratio experienced a moderate decline to 5.59 in 2020 before recovering slightly to 5.71 by the end of 2021. This pattern suggests a steady rate of credit recovery relative to sales.
- Average Receivable Collection Period
- The collection period remained stable, oscillating between 60 and 66 days. The most efficient collection cycle was observed in 2019, with an average collection period of 60 days. This was followed by a slight increase to 65 days in 2020 and a marginal improvement to 64 days in 2021. The narrow variance in these figures indicates a disciplined and predictable credit collection process.
Overall, the inverse relationship between the turnover ratio and the collection period remains constant across the observed timeframe. The consistency of these metrics suggests that the company's credit policies and the payment behavior of its customers have remained largely unchanged, ensuring a reliable short-term cash flow from operations.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Cycle
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 234 | 216 | 150 | 187 | 202 | |
| Average receivable collection period | 64 | 65 | 60 | 66 | 63 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 298 | 281 | 210 | 253 | 265 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 130 | — | — | — | — | |
| Amgen Inc. | 305 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 142 | — | — | — | — | |
| Danaher Corp. | 145 | — | — | — | — | |
| Eli Lilly & Co. | 280 | — | — | — | — | |
| Gilead Sciences Inc. | 150 | — | — | — | — | |
| Johnson & Johnson | 186 | — | — | — | — | |
| Merck & Co. Inc. | 228 | — | — | — | — | |
| Pfizer Inc. | 158 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 429 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 168 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 198 | — | — | — | — | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 183 | — | — | — | — | |
| Operating Cycle, Industry | ||||||
| Health Care | 92 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 234 + 64 = 298
2 Click competitor name to see calculations.
The operating cycle exhibits significant volatility over the five-year period, characterized by an initial contraction followed by a marked expansion. The total duration of the cycle decreased from 265 days in 2017 to a low of 210 days in 2019, before increasing to 298 days by the end of 2021.
- Average Inventory Processing Period
- The inventory processing period serves as the primary driver of the fluctuations in the overall operating cycle. A downward trend was observed between 2017 and 2019, during which the period decreased from 202 days to 150 days. However, this trend reversed sharply after 2019, with the period escalating to 216 days in 2020 and further to 234 days in 2021. This indicates a substantial increase in the time required to convert inventory into sales.
- Average Receivable Collection Period
- Receivable collection remained remarkably stable throughout the analyzed period. The collection timeframe fluctuated within a narrow range of 60 to 66 days, indicating a consistent and predictable credit collection process. This stability suggests that the company's accounts receivable management has remained constant regardless of the changes in inventory turnover.
- Operating Cycle Synthesis
- The overall operating cycle expanded by 88 days between the 2019 low and the 2021 peak. This expansion is almost exclusively attributable to the increase in the inventory processing period, as the receivable collection period remained nearly flat. The extension of the cycle to 298 days by 2021 indicates a lengthening of the timeframe between the initial outlay for inventory and the final realization of cash from customers.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Payables Payment Period
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 3.58 | 3.97 | 3.68 | 4.90 | 4.12 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 102 | 92 | 99 | 74 | 89 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 60 | — | — | — | — | |
| Amgen Inc. | 77 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 108 | — | — | — | — | |
| Danaher Corp. | 82 | — | — | — | — | |
| Eli Lilly & Co. | 83 | — | — | — | — | |
| Gilead Sciences Inc. | 39 | — | — | — | — | |
| Johnson & Johnson | 135 | — | — | — | — | |
| Merck & Co. Inc. | 123 | — | — | — | — | |
| Pfizer Inc. | 66 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 84 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 53 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 79 | — | — | — | — | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 86 | — | — | — | — | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 63 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.58 = 102
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a general extension of the timeframe required to settle obligations to suppliers between 2017 and 2021. While a period of increased payment efficiency was observed in 2018, the subsequent years demonstrate a trend toward longer payment cycles, suggesting a shift in the management of accounts payable.
- Payables Turnover Trends
- The payables turnover ratio experienced volatility over the five-year period. After starting at 4.12 in 2017, the ratio peaked in 2018 at 4.90, indicating the highest frequency of supplier payments within the analyzed timeframe. However, a subsequent decline occurred, with the ratio falling to 3.68 in 2019 and reaching a period low of 3.58 by December 31, 2021. This downward trajectory reflects a reduction in the velocity at which liabilities are cleared.
- Average Payables Payment Period Analysis
- The average duration for settling payables exhibits a direct inverse correlation with the turnover ratio. The payment period decreased from 89 days in 2017 to a minimum of 74 days in 2018. Following this low, the period expanded sharply to 99 days in 2019. Despite a moderate reduction to 92 days in 2020, the period climbed to its highest level of 102 days by the end of 2021.
- Operational Implications
- The transition from a 74-day payment cycle in 2018 to a 102-day cycle in 2021 indicates an increase in the average time taken to pay creditors. This extension of the payment period suggests a strategy to conserve cash flow and optimize working capital by utilizing supplier credit for longer durations. The increase of 28 days between the 2018 low and 2021 high represents a significant slowing of cash outflows related to operating payables.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Cash Conversion Cycle
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 234 | 216 | 150 | 187 | 202 | |
| Average receivable collection period | 64 | 65 | 60 | 66 | 63 | |
| Average payables payment period | 102 | 92 | 99 | 74 | 89 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 196 | 189 | 111 | 179 | 176 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 70 | — | — | — | — | |
| Amgen Inc. | 228 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 34 | — | — | — | — | |
| Danaher Corp. | 63 | — | — | — | — | |
| Eli Lilly & Co. | 197 | — | — | — | — | |
| Gilead Sciences Inc. | 111 | — | — | — | — | |
| Johnson & Johnson | 51 | — | — | — | — | |
| Merck & Co. Inc. | 105 | — | — | — | — | |
| Pfizer Inc. | 92 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 345 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 115 | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | 119 | — | — | — | — | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 97 | — | — | — | — | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 29 | — | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 234 + 64 – 102 = 196
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a non-linear trend over the five-year period, characterized by a significant optimization in 2019 followed by a steady deterioration in efficiency through 2021.
- Average Inventory Processing Period
- A fluctuating pattern is observed, with a notable decline from 202 days in 2017 to a minimum of 150 days in 2019. However, this efficiency was reversed in the subsequent two years, with the period extending to 234 days by the end of 2021. This metric represents the primary driver of volatility within the operating cycle.
- Average Receivable Collection Period
- Collection efficiency remained remarkably stable throughout the analysis period. The duration fluctuated minimally between 60 and 66 days, indicating consistent credit management and a predictable cadence in converting receivables into cash.
- Average Payables Payment Period
- Payment terms experienced moderate volatility, dipping to 74 days in 2018 before trending upward to 102 days in 2021. The general increase in this period suggests a strategic extension of payment terms to suppliers, which serves to mitigate some of the liquidity pressure caused by slower inventory turnover.
- Cash Conversion Cycle
- The overall cycle reached a five-year peak of 196 days in 2021, having risen sharply from a low of 111 days in 2019. The expansion of the cycle indicates a decrease in working capital efficiency, as the significant increase in inventory holding time outweighed the benefits gained from the extended payables payment period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?